MANAGEMENT OF SEVERE PULMONARY COMPLICATIONS FOLLOWING HSCT IN A PATIENT WITH Β-THALASSEMIA: A CASE REPORT ON SUCCESSFUL TREATMENT OF CMV PNEUMONIA, DAH, AND BOS (EBMT 2026) - Feb 7, 2026 - Abstract #P216; Pres time: Mar 22, 2026; 08:30 AM - 06:00 PM; Location: ePoster Area; "She underwent a matched unrelated donor (9/10 HLA-matched) allo-HSCT following a myeloablative conditioning regimen (fludarabine, busulfan, cyclophosphamide, ATG). GVHD prophylaxis included tacrolimus, methotrexate, mycophenolate mofetil, and pre-emptive infusions of umbilical cord-derived mesenchymal stromal cells (UC-MSCs)...The early post-transplant course was complicated by steroid-refractory, grade III acute GVHD (skin and gut), which was successfully managed with a second-line regimen of ruxolitinib, CD25 monoclonal antibody, budesonide, and additional UC-MSCs...Initial anti-CMV therapy (acyclovir/foscarnet) failed, indicating a refractory infection...Treatment with the FAM regimen (fluticasone, azithromycin, montelukast) combined with further cycles of UC-MSCs resulted in significant clinical and radiological improvement by day +220... This complex case illustrates the cascade of severe complications—refractory aGVHD, life-threatening CMV pneumonia with DAH,..."
Case report • Clinical • Acute Graft versus Host Disease • Beta-Thalassemia • Bone Marrow Transplantation • Genetic Disorders • Graft versus Host Disease • Hematological Disorders • Immunology • Infectious Disease • Pneumonia • Pulmonary Disease • Respiratory Diseases
|
|
Li Li1; Ting Chen1; Peiyan Kong1; Xi Zhang1; Yimei Feng1
|